The stack peptide clinics actually sell: CJC-1295 + ipamorelin, and the evidence behind it

Editorial evidence review — August 22, 2026

If you ask a longevity clinic, a men’s-health telehealth platform, or a wellness influencer what “peptide therapy” means in practice, the answer — more often than any other single product — is a vial labeled CJC-1295 / ipamorelin. The combination is marketed as a gentler, “more physiologic” alternative to growth hormone: two secretagogues that coax your own pituitary into producing more GH, sold for sleep, recovery, body composition, and aging itself. It is arguably the flagship product of the gray-market peptide economy we have covered before.

Here is the thing almost nobody buying it is told: the complete published human evidence for these two compounds is four small studies. The newest is from 2014. Not one measured the outcomes the stack is sold for. The combination itself — the actual product, two drugs co-injected — has never been tested in a published human trial at all. And in late 2024, an FDA advisory committee reviewed both compounds and voted, nearly unanimously, against allowing pharmacies to compound them.

This site exists to check the sales pitch against the literature. For the most-sold stack in the peptide economy, the gap between the two is unusually wide, and worth walking through carefully.

What the two compounds actually are

The pairing bundles two different mechanisms aimed at the same hormone.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), engineered with a “drug affinity complex” (DAC) that covalently binds the peptide to albumin in the blood, stretching its half-life from minutes to days. It was developed in the mid-2000s by a Canadian biotech, ConjuChem, as a once-weekly alternative to daily GH injections. A complication worth knowing: much of what clinics sell as “CJC-1295 without DAC” is a different, shorter-acting molecule — modified GRF(1-29) — that shares the name for marketing reasons (FDA nomination materials, 2024). When a product label says CJC-1295, which molecule is in the vial is a genuinely open question.

Ipamorelin works on the other arm of the axis. It is a pentapeptide agonist of the ghrelin receptor — the same target as MK-677 and hexarelin — first described by Novo Nordisk researchers in 1998 as “the first selective growth hormone secretagogue” (Raun et al., European Journal of Endocrinology). In rats and swine, it triggered GH release without the cortisol and ACTH spikes of earlier GHRPs. That animal-pharmacology finding is the entire origin of the “cleanest secretagogue” reputation the compound enjoys online. It has never been demonstrated as a clinical advantage in humans.

The theory of the stack is that a GHRH analog plus a ghrelin-receptor agonist stimulate GH synergistically through complementary pathways. The theory is plausible. The evidence is where things get thin.

The entire human evidence base, itemized

This is not a selection. As of this writing, these four studies are essentially the complete published human literature on the two compounds.

Teichman et al., 2006. Two randomized, placebo-controlled, ascending-dose trials of CJC-1295 in healthy adults aged 21 to 61, lasting 28 and 49 days (Journal of Clinical Endocrinology & Metabolism). A single injection raised mean GH concentrations 2- to 10-fold and IGF-1 1.5- to 3-fold, with IGF-1 staying elevated for nine to eleven days; the half-life came in at 5.8 to 8.1 days. This is a real, well-run pharmacology study — and it measured hormone levels, not outcomes.

Ionescu and Frohman, 2006. A 12-hour overnight sampling study in healthy men showing that GH secretion remained pulsatile — rather than flat-lining — under continuous CJC-1295 stimulation (JCEM). This is the study behind every “it works with your body’s natural rhythms” claim in clinic marketing. It was a short physiology experiment in healthy young men.

Gobburu et al., 1999, and the early ipamorelin work. A pharmacokinetic-pharmacodynamic study in healthy male volunteers established that intravenous ipamorelin produces a GH pulse. Again: a hormone response, in a lab, over hours.

Beck et al., 2014. The only patient trial with a clinical endpoint either compound has ever had published: a multicenter, double-blind, placebo-controlled phase 2 trial of ipamorelin for postoperative ileus after bowel resection, in 117 patients (International Journal of Colorectal Disease). Median time to a first tolerated meal was 25.3 hours on ipamorelin versus 32.6 on placebo — a difference that was not statistically significant, on the primary endpoint or the secondaries. The development program was discontinued.

That is the record. No trial of the combination. No trial in the populations the stack is actually sold to. No body-composition, sleep-architecture, recovery, strength, or longevity outcome ever published for either molecule. Every claim on a clinic menu about what CJC-1295/ipamorelin does for you is an extrapolation from hormone curves in small groups of healthy volunteers, most of it two decades old.

The safety file is thinner than the efficacy file — and darker

The honest description of the stack’s safety profile is not “proven dangerous.” It is “never characterized,” with a few data points that should command attention.

A trial death ended CJC-1295’s development. In July 2006, ConjuChem’s phase 2 trial of CJC-1295 in HIV-associated lipodystrophy (NCT00267527, 192 participants enrolled) was halted after a participant died of a myocardial infarction roughly three hours after his eleventh weekly dose. The attending physician’s assessment was pre-existing asymptomatic coronary disease with plaque rupture, and the sponsor judged a direct drug relationship unlikely — but the program was terminated, and the trial data were never published. The FDA’s December 2024 briefing document notes that those unpublished data were not even available for the agency’s own review. Twenty years later, the compound’s largest-ever human safety dataset remains a black box.

The small studies were not spotless. In the FDA’s review of the published CJC-1295 work, adverse events included injection-site reactions, headache, flushing, transient hypotension, and — in the pulsatility study — dose-dependent increases in heart rate; the agency concluded that some findings warranted further study, particularly in people at risk for heart disease. For ipamorelin, FDA’s compounding safety-risk page cites literature reports of serious adverse events, including death, with intravenous use for gastric motility, along with immunogenicity and impurity concerns for compounded product.

The class physiology cuts against casual use. The stack’s purpose is to raise GH and IGF-1 in healthy adults — which is the one intervention in this space with a genuinely instructive evidence history. When actual recombinant growth hormone was systematically tested in the healthy elderly, a 2007 systematic review in the Annals of Internal Medicine (Liu et al.) found small body-composition changes, no functional benefit, and a consistent burden of harms: edema, arthralgias, carpal tunnel syndrome, and a trend toward new-onset glucose intolerance. An accompanying Annals editorial on secretagogues was titled, bluntly, “Not Yet Ready for Prime Time”. If elevating this axis pharmacologically delivered what the stack promises, GH itself would have shown it. It did not — and with CJC-1295’s DAC version, you get the added wrinkle of IGF-1 held above baseline continuously for weeks, a state whose long-term safety in healthy people has simply never been studied.

None of this establishes that the stack is harming its users. What it establishes is that nobody is in a position to say it isn’t — which, for a product injected daily by healthy people on an open-ended timeline, is itself the finding.

The regulators have now weighed in, and it wasn’t close

The compounds’ regulatory year has been quietly decisive, and it points the opposite direction from the July 2026 PCAC votes on BPC-157 and its cohort that made headlines.

At the FDA Pharmacy Compounding Advisory Committee’s October 29, 2024 meeting, the panel voted 0 yes, 12 no, 1 abstention against placing ipamorelin (both free base and acetate) on the 503A bulks list — the roster of substances pharmacies may legally compound from — citing the lack of safety and efficacy information for the nominated uses. At the December 4, 2024 meeting, CJC-1295 fared the same or worse: 0–13 for the free base, 1–12 for the acetate, 0–13 for the DAC forms. Recall that this is the same committee that later voted for six of seven research peptides in July 2026, over the objection of FDA’s own scientists. Even a panel that lenient looked at the two best-selling peptides in the clinic economy and declined, near-unanimously.

The practical status today, as detailed on our CJC-1295 and ipamorelin pages: neither compound is FDA-approved, neither appears on the 503A bulks list, ipamorelin acetate sits in FDA’s 503B Category 2 significant-safety-risk bucket, and FDA’s April 2026 category update left both without any compliant compounding pathway. The stack that anchors thousands of clinic menus has, at this point, no legal U.S. supply chain — which tells you something about the sourcing of what is actually in circulation.

The irony: this drug family contains a real, approved drug

What makes the stack’s dominance genuinely strange is that the GHRH-analog family is not some evidence-free frontier. It contains one of the few peptides in this entire space with an approval-grade record.

Tesamorelin — a GHRH analog, mechanistically CJC-1295’s close cousin — was FDA-approved in November 2010 as Egrifta, on the strength of two randomized, placebo-controlled phase 3 trials in 816 patients showing reduced visceral fat in HIV-associated lipodystrophy. Sermorelin, an older GHRH fragment, was itself an approved product (Geref) for years before being discontinued for commercial reasons. If a clinician believes a patient genuinely needs GHRH-axis therapy, a version with published phase 3 trials, a real label, contraindications, and pharmaceutical-grade manufacturing exists.

The stack does not persist because the evidence favors it over these. It persists because it is cheap, unpatented, easy to source from gray-market suppliers, and unencumbered by the diagnostic gatekeeping an approved drug carries. Those are supply-chain advantages, not clinical ones — and they are precisely the attributes that correlate with the product-quality problems we have documented across this market.

The bottom line

CJC-1295 and ipamorelin are real pharmacology: both reliably raise growth hormone, and the studies showing it are legitimate. Everything past that sentence is unsupported. Four small human studies, none testing the combination, none measuring a single outcome the stack is marketed for, a development program ended by an unexplained trial death whose data remain unpublished, an FDA advisory committee voting 0–12 and 0–13 against the compounds, and no legal U.S. pathway to obtain them. Meanwhile the same drug family contains an actual FDA-approved option that the stack’s marketing rarely mentions. “Boosts your own growth hormone” is true, and it is doing an enormous amount of work in place of the questions that matter — by how much, for whose benefit, at what risk, and compared to what. On the most-sold peptide product in the wellness economy, the literature’s answer to all four is: nobody has checked.

This is an editorial evidence review, not medical advice. Decisions about hormone therapies belong with a licensed clinician who can weigh your individual history — and who can tell you which of these compounds has an FDA label and which does not.